tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Jan 1;10(1):67.
doi: 10.3390/vaccines10010067.
Development of an Oral Salmonella-Based Vaccine Platform against SARS-CoV-2
Wonsuck Yoon[SUP] 1 2 [/SUP], Yongsung Park[SUP] 3 [/SUP], Seunghyun Kim[SUP] 1 [/SUP], Iel Soo Bang[SUP] 4 [/SUP]
Affiliations
Abstract
Effective vaccine development for global outbreaks, such as the coronavirus disease 2019 (COVID-19), has been successful in the short run. However, the currently available vaccines have been associated with a higher frequency of adverse effects compared with other general vaccines. In this study, the possibility of an oral bacteria-based vaccine that can be safely used as a platform for large-scale, long-term immunization was evaluated. A well-known Salmonella strain that was previously considered as a vaccine delivery candidate was used. Recombinant Salmonella cells expressing engineered viral proteins related with COVID-19 pathogenesis were engineered, and the formulation of the oral vaccine candidate strain was evaluated by in vitro and in vivo experiments. First, engineered S proteins were synthesized and cloned into expression vectors, which were than transformed into Salmonella cells. In addition, when orally administrated to mice, the vaccine promoted antigen-specific antibody production and cellular immunity was induced with no significant toxicity effects. These results suggest that Salmonella strains may represent a valuable platform for the development of an oral vaccine for COVID-19 as an alternative to tackle the outbreak of various mutated coronavirus strains and new infectious diseases in the future.
Keywords: SARS-CoV-2; Salmonella; oral vaccine; spike protein.
. 2022 Jan 1;10(1):67.
doi: 10.3390/vaccines10010067.
Development of an Oral Salmonella-Based Vaccine Platform against SARS-CoV-2
Wonsuck Yoon[SUP] 1 2 [/SUP], Yongsung Park[SUP] 3 [/SUP], Seunghyun Kim[SUP] 1 [/SUP], Iel Soo Bang[SUP] 4 [/SUP]
Affiliations
- PMID: 35062728
- DOI: 10.3390/vaccines10010067
Abstract
Effective vaccine development for global outbreaks, such as the coronavirus disease 2019 (COVID-19), has been successful in the short run. However, the currently available vaccines have been associated with a higher frequency of adverse effects compared with other general vaccines. In this study, the possibility of an oral bacteria-based vaccine that can be safely used as a platform for large-scale, long-term immunization was evaluated. A well-known Salmonella strain that was previously considered as a vaccine delivery candidate was used. Recombinant Salmonella cells expressing engineered viral proteins related with COVID-19 pathogenesis were engineered, and the formulation of the oral vaccine candidate strain was evaluated by in vitro and in vivo experiments. First, engineered S proteins were synthesized and cloned into expression vectors, which were than transformed into Salmonella cells. In addition, when orally administrated to mice, the vaccine promoted antigen-specific antibody production and cellular immunity was induced with no significant toxicity effects. These results suggest that Salmonella strains may represent a valuable platform for the development of an oral vaccine for COVID-19 as an alternative to tackle the outbreak of various mutated coronavirus strains and new infectious diseases in the future.
Keywords: SARS-CoV-2; Salmonella; oral vaccine; spike protein.